Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab and Plaque Regression in PAD
NCT02959047Phase 4Completed
- Sponsor
- University of Virginia
- Start
- Jul 2017
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Peripheral Arterial Disease (PAD) comparing Alirocumab with Placebo (2 arms). Primary endpoint: Change in superficial femoral plaque volume at 1 year. Started Jul 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT02959047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959047.